IL-6 biology: implications for clinical targeting in rheumatic disease

IL-6 has been linked to numerous diseases associated with inflammation, including rheumatoid arthritis, inflammatory bowel disease, vasculitis and several types of cancer. Moreover, IL-6 is important in the induction of hepatic acute-phase proteins for the trafficking of acute and chronic inflammatory cells, the differentiation of adaptive T-cell responses, and tissue regeneration and homeostatic regulation. Studies have investigated IL-6 biology using cell-bound IL-6 receptors expressed predominantly on hepatocytes and certain haematopoietic cells versus activation mediated by IL-6 and soluble IL-6 receptors via a second protein, gp130, which is expressed throughout the body. Advances in this research elucidating the differential effects of IL-6 activation provide important insights into the role of IL-6 in health and disease, as well as its potential as a therapeutic target. Knowledge of the basic biology of IL-6 and its signalling pathways can better inform both the research agenda for IL-6-based targeted therapies as well as the clinical use of strategies affecting IL-6-mediated inflammation. This Review covers novel, emerging aspects of the biology of IL-6, which might lead to more specific blockade of IL-6 signalling without compromising the protective function of this cytokine in the body's defence against infections.

[1]  T. S. Wilkinson,et al.  Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.

[2]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[3]  I. McInnes,et al.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm , 2013, Nature Reviews Rheumatology.

[4]  C. Jorgensen,et al.  Interleukin‐6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis , 2014, Arthritis & rheumatology.

[5]  S. Kaufmann,et al.  Copyright © 1997, American Society for Microbiology Lethal Tuberculosis in Interleukin-6-Deficient Mutant Mice , 1997 .

[6]  J. Scheller,et al.  IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling , 2013, The Journal of Immunology.

[7]  M. Rincón,et al.  Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells1 , 2008, The Journal of Immunology.

[8]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.

[9]  J. Scheller,et al.  Interleukin-6 and its receptor: from bench to bedside , 2006, Medical Microbiology and Immunology.

[10]  M. Febbraio,et al.  Is Interleukin‐6 Receptor Blockade the Holy Grail for Inflammatory Diseases? , 2010, Clinical pharmacology and therapeutics.

[11]  P. Schirmacher,et al.  Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice , 2010, The Journal of experimental medicine.

[12]  F. Breedveld,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 , 2006, Annals of the rheumatic diseases.

[13]  G. Yancopoulos,et al.  Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) , 2014, Annals of the rheumatic diseases.

[14]  M. Laudes,et al.  Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases , 2010, PloS one.

[15]  S. Rose-John,et al.  The regenerative activity of interleukin-6. , 2013, Methods in molecular biology.

[16]  T. Hirano,et al.  Studies on the structure and regulation of the human hepatic interleukin-6 receptor. , 1990, European journal of biochemistry.

[17]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[18]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 , 2013, Annals of the rheumatic diseases.

[19]  N. Nishimoto,et al.  Interleukin‐6 as a Therapeutic Target in Candidate Inflammatory Diseases , 2010, Clinical pharmacology and therapeutics.

[20]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[21]  R. Kyle,et al.  Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. , 1992, Cytokine.

[22]  K. Hagihara,et al.  Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica , 2010, The Journal of Rheumatology.

[23]  R. Marquet,et al.  Interleukin-6: historical background, genetics and biological significance. , 1990, Immunology letters.

[24]  S. Boekholdt,et al.  The interleukin-6 pathway and atherosclerosis , 2012, The Lancet.

[25]  Stefan Rose-John,et al.  ADAM17: a molecular switch to control inflammation and tissue regeneration. , 2011, Trends in immunology.

[26]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[27]  P. Schirmacher,et al.  Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. , 2000, Gastroenterology.

[28]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[29]  Stefan Rose-John,et al.  Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)* , 2003, Journal of Biological Chemistry.

[30]  P. Lipsky,et al.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. , 2010, Arthritis and rheumatism.

[31]  M. Neurath,et al.  IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer , 2005, Cell cycle.

[32]  M. Dougados,et al.  Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials , 2013, Annals of the rheumatic diseases.

[33]  S. Rose-John,et al.  Neural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors , 1999, The European journal of neuroscience.

[34]  I. McInnes,et al.  Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study , 2013, Annals of the rheumatic diseases.

[35]  A. Yoshimura,et al.  IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. , 2013, The Journal of clinical investigation.

[36]  M. Dougados,et al.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions , 2012, Annals of the rheumatic diseases.

[37]  H. Hartung,et al.  Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. , 2013, JAMA neurology.

[38]  Timothy Pearson,et al.  A Focused Review of the Literature , 2014 .

[39]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews. , 2009, The Cochrane database of systematic reviews.

[40]  M. Sata,et al.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice , 2006, Gut.

[41]  S. Rose-John,et al.  Sympathetic neurons can produce and respond to interleukin 6. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Weyand,et al.  Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.

[43]  K. Garcia,et al.  Structure of an Extracellular gp130 Cytokine Receptor Signaling Complex , 2001, Science.

[44]  Cindy L. Miller,et al.  Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Scheller,et al.  Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. , 2014, Seminars in immunology.

[46]  N. Nishimoto,et al.  The value of blocking IL-6 outside of rheumatoid arthritis: current perspective , 2011, Current opinion in rheumatology.

[47]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[48]  J. Singh,et al.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. , 2013, Immunotherapy.

[49]  M. Neurath,et al.  Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25− T Cells1 , 2007, The Journal of Immunology.

[50]  M. Spehlmann,et al.  Trp53 Deficiency Protects against Acute Intestinal Inflammation , 2013, The Journal of Immunology.

[51]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[52]  Amit Awasthi,et al.  IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[53]  S. Gabriel,et al.  Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives , 2010, Annals of the rheumatic diseases.

[54]  S. Rose-John.  IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 , 2012, International journal of biological sciences.

[55]  P. Rosenstiel,et al.  Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model* , 2011, Critical care medicine.

[56]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[57]  J. Scheller,et al.  Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. , 2012, Immunobiology.

[58]  H. Boysson,et al.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence , 2012, Clinical Rheumatology.

[59]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[60]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[61]  C. Fielding,et al.  Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. , 2007, Blood.

[62]  S. Bandinelli,et al.  A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects , 2007, Genes and Immunity.

[63]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[64]  M. Sata,et al.  Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model , 2009, The Journal of Immunology.

[65]  N. Krug,et al.  The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. , 2005, The Journal of clinical investigation.

[66]  J. Kremer,et al.  Integrated safety in tocilizumab clinical trials , 2011, Arthritis research & therapy.

[67]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[68]  T. Kishimoto.  Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[69]  J. Smolen,et al.  Inflammatory bone loss: pathogenesis and therapeutic intervention , 2012, Nature Reviews Drug Discovery.

[70]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[71]  M. Waki,et al.  Soluble interleukin‐6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism , 1994, European journal of immunology.

[72]  L. Magnani,et al.  Tocilizumab: a novel therapy for patients with large-vessel vasculitis. , 2012, Rheumatology.

[73]  Toshio Tanaka,et al.  Therapeutic targeting of the interleukin-6 receptor. , 2012, Annual review of pharmacology and toxicology.

[74]  J. Scheller,et al.  Updating interleukin-6 classic- and trans-signaling , 2006 .

[75]  M. Dougados,et al.  Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement , 2012, Annals of the rheumatic diseases.

[76]  S. Rose-John,et al.  Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. , 1999, Journal of immunology.

[77]  P. Heinrich,et al.  Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. , 1992, Biochemical and biophysical research communications.

[78]  S. Rose-John,et al.  Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. , 2000, Virology.

[79]  B. Cronstein.  Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. , 2007, Bulletin of the NYU hospital for joint diseases.

[80]  D. Furst,et al.  Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. , 2014, Seminars in arthritis and rheumatism.

[81]  M. Kawai,et al.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab , 2010, Rheumatology.

[82]  P. Heinrich,et al.  The soluble interleukin‐6 receptor is generated by shedding , 1993, European journal of immunology.

[83]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[84]  Daniel F. Freitag,et al.  Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases , 2013, PLoS genetics.

[85]  A. Bengtsson,et al.  Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. , 2013, Arthritis and rheumatism.

[86]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[87]  J. Scheller,et al.  Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis1 , 2009, The Journal of Immunology.

[88]  M. Genovese,et al.  Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial , 2013, Annals of the rheumatic diseases.

[89]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[90]  F. Annunziato,et al.  Heterogeneity of human effector CD4+ T cells , 2009, Arthritis research & therapy.

[91]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[92]  S. Rose-John,et al.  Hitting a complex target: an update on interleukin-6 trans-signalling , 2012, Expert opinion on therapeutic targets.

[93]  P. Emery,et al.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial , 2013, The Lancet.

[94]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[95]  S. Rose-John,et al.  Hyper-IL-6 gene therapy reverses fulminant hepatic failure. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  S. Unizony,et al.  Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica , 2012, Arthritis care & research.

[97]  Soon-Cheang Quah,et al.  A Current Perspective , 2007 .

[98]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.